Quantitative Determination of Pravastatin and Its Metabolite 3α-hydroxy Pravastatin in Plasma and Urine of Pregnant Patients by LC-MS/MS

Overview

Journal Biomed Chromatogr

Publisher Wiley

Specialties Biology
Chemistry

Date 2015 Sep 12

PMID 26360932

Citations 6

Authors

Xing Zhang

Daria I Vernikovskaya

Xiaoming Wang

Tatiana N Nanovskaya

Maged Costantine

Gary D V Hankins

Mahmoud S Ahmed

Affiliations

Soon will be listed here.

Abstract

This report describes the development and validation of a chromatography/tandem mass spectrometry method for the quantitative determination of pravastatin and its metabolite (3α-hydroxy pravastatin) in plasma and urine of pregnant patients under treatment with pravastatin, as part of a clinical trial. The method includes a one-step sample preparation by liquid-liquid extraction. The extraction recovery of the analytes ranged between 93.8 and 99.5% in plasma. The lower limits of quantitation of the analytes in plasma samples were 0.106 ng/mL for pravastatin and 0.105 ng/mL for 3α-hydroxy pravastatin, while in urine samples they were 19.7 ng/mL for pravastatin and 2.00 ng/mL for 3α-hydroxy pravastatin. The relative deviation of this method was <10% for intra- and interday assays in plasma and urine samples, and the accuracy ranged between 97.2 and 106% in plasma, and between 98.2 and 105% in urine. The method described in this report was successfully utilized for determining the pharmacokinetics of pravastatin in pregnant patients enrolled in a pilot clinical trial for prevention of preeclampsia.

Citing Articles

Microfluidic technology and simulation models in studying pharmacokinetics during pregnancy.

Kammala A, Richardson L, Radnaa E, Han A, Menon R Front Pharmacol. 2023; 14:1241815.

PMID: 37663251 PMC: 10469630. DOI: 10.3389/fphar.2023.1241815.

Testing of drugs using human feto-maternal interface organ-on-chips provide insights into pharmacokinetics and efficacy.

Richardson L, Kammala A, Costantine M, Fortunato S, Radnaa E, Kim S Lab Chip. 2022; 22(23):4574-4592.

PMID: 36322152 PMC: 9682442. DOI: 10.1039/d2lc00691j.

Gut Microbial Metabolite Pravastatin Attenuates Intestinal Ischemia/Reperfusion Injury Through Promoting IL-13 Release From Type II Innate Lymphoid Cells IL-33/ST2 Signaling.

Deng F, Hu J, Yang X, Sun Q, Lin Z, Zhao B Front Immunol. 2021; 12:704836.

PMID: 34650552 PMC: 8505964. DOI: 10.3389/fimmu.2021.704836.

Role of Uptake Transporters OAT4, OATP2A1, and OATP1A2 in Human Placental Bio-disposition of Pravastatin.

Fokina V, Patrikeeva S, Wang X, Noguchi S, Tomi M, Konig J J Pharm Sci. 2021; 111(2):505-516.

PMID: 34597623 PMC: 8792198. DOI: 10.1016/j.xphs.2021.09.035.

A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia.

Costantine M, West H, Wisner K, Caritis S, Clark S, Venkataramanan R Am J Obstet Gynecol. 2021; 225(6):666.e1-666.e15.

PMID: 34033812 PMC: 8611118. DOI: 10.1016/j.ajog.2021.05.018.

References

Mulvana D, Jemal M, Pulver S . Quantitative determination of pravastatin and its biotransformation products in human serum by turbo ion spray LC/MS/MS. J Pharm Biomed Anal. 2000; 23(5):851-66. DOI: 10.1016/s0731-7085(00)00372-1. View

Hatanaka T . Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet. 2001; 39(6):397-412. DOI: 10.2165/00003088-200039060-00002. View

Frederiksen M . Physiologic changes in pregnancy and their effect on drug disposition. Semin Perinatol. 2001; 25(3):120-3. DOI: 10.1053/sper.2001.24565. View

Zhu Z, Neirinck L . High-performance liquid chromatography coupled with negative ion tandem mass spectrometry for determination of pravastatin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2002; 783(1):133-40. DOI: 10.1016/s1570-0232(02)00526-3. View

Schachter M . Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005; 19(1):117-25. DOI: 10.1111/j.1472-8206.2004.00299.x. View

Kawabata K, Samata N, Urasaki Y . Quantitative determination of pravastatin and R-416, its main metabolite in human plasma, by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 816(1-2):73-9. DOI: 10.1016/j.jchromb.2004.11.014. View

Bauer S, Mwinyi J, Stoeckle A, Gerloff T, Roots I . Quantification of pravastatin in human plasma and urine after solid phase extraction using high performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 818(2):257-62. DOI: 10.1016/j.jchromb.2005.01.006. View

Everett D, Chando T, DiDonato G, Singhvi S, Pan H, Weinstein S . Biotransformation of pravastatin sodium in humans. Drug Metab Dispos. 1991; 19(4):740-8. View

Unadkat J, Wara D, Hughes M, Mathias A, Holland D, Paul M . Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2006; 51(2):783-6. PMC: 1797783. DOI: 10.1128/AAC.00420-06. View

10.

Costenbader K, Liang M, Chibnik L, Aizer J, Kwon H, Gall V . A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol Int. 2007; 27(11):1071-7. DOI: 10.1007/s00296-007-0341-6. View

11.

Vlckova H, Rabatinova M, Miksova A, Kolouchova G, Micuda S, Solich P . Determination of pravastatin and pravastatin lactone in rat plasma and urine using UHPLC-MS/MS and microextraction by packed sorbent. Talanta. 2012; 90:22-9. DOI: 10.1016/j.talanta.2011.12.043. View

12.

Hulskotte E, Feng H, Xuan F, Gupta S, van Zutven M, OMara E . Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin. Antimicrob Agents Chemother. 2013; 57(6):2582-8. PMC: 3716144. DOI: 10.1128/AAC.02347-12. View

13.

Rao Polagani S, Pilli N, Gandu V . High performance liquid chromatography mass spectrometric method for the simultaneous quantification of pravastatin and aspirin in human plasma: Pharmacokinetic application. J Pharm Anal. 2018; 2(3):206-213. PMC: 5760909. DOI: 10.1016/j.jpha.2012.01.001. View

14.

Ito M . Effects of extensive and poor gastrointestinal metabolism on the pharmacodynamics of pravastatin. J Clin Pharmacol. 1998; 38(4):331-6. DOI: 10.1002/j.1552-4604.1998.tb04432.x. View

15.

Sigurbjornsson S, Kjartansdottir T, Johannsson M, Kristinsson J, Sigurdsson G . A pharmacokinetic evaluation of pravastatin in middle-aged and elderly volunteers. Eur J Drug Metab Pharmacokinet. 1998; 23(1):13-8. DOI: 10.1007/BF03189821. View

16.

Jemal M, Xia Y, Whigan D . The use of high-flow high performance liquid chromatography coupled with positive and negative ion electrospray tandem mass spectrometry for quantitative bioanalysis via direct injection of the plasma/serum samples. Rapid Commun Mass Spectrom. 1998; 12(19):1389-99. DOI: 10.1002/(SICI)1097-0231(19981015)12:19<1389::AID-RCM329>3.0.CO;2-T. View

17.

Kawabata K, Matsushima N, Sasahara K . An automated method for the simultaneous determination of pravastatin and its main metabolite in human plasma by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. Biomed Chromatogr. 1998; 12(5):271-5. DOI: 10.1002/(SICI)1099-0801(199809/10)12:5<271::AID-BMC746>3.0.CO;2-F. View